menu

Medical Program: REMS-Required Drug Monitoring During the COVID-19 Pandemic

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

REMS-Required Drug Monitoring During the COVID-19 Pandemic

close
REMS-Required Drug Monitoring During the COVID-19 Pandemic
Restart
Resume
Choose a format
Media formats available:
Details
Presenters
Comments
  • Overview

    The Food and Drug Administration has issued a guidance on its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements during the COVID-19 pandemic that include laboratory monitoring and imaging studies. Pharmacist Dr. Linda Bernstein discusses the guidance and its impact on patient access to certain REMS drugs when patients self-isolate or are subject to quarantine due to COVID-19.

    Published April 17, 2020

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    The Food and Drug Administration has issued a guidance on its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements during the COVID-19 pandemic that include laboratory monitoring and imaging studies. Pharmacist Dr. Linda Bernstein discusses the guidance and its impact on patient access to certain REMS drugs when patients self-isolate or are subject to quarantine due to COVID-19.

    Published April 17, 2020

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 7/12/20